(Q38005612)

26 August 2017

title

The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens (English)

1 reference

26 August 2017

A Carracedo

10

0 references

author name string

M J Lamas

1

1 reference

26 August 2017

G Duran

2

1 reference

26 August 2017

E Balboa

3

1 reference

26 August 2017

B Bernardez

4

1 reference

26 August 2017

S Candamio

5

1 reference

26 August 2017

Y Vidal

6

1 reference

26 August 2017

A Mosquera

7

1 reference

26 August 2017

J M Giraldez

8

1 reference

26 August 2017

R Lopez

9

1 reference

26 August 2017

F Barros

11

1 reference

26 August 2017

publication date

26 April 2012

1 reference

Cancer Chemotherapy and Pharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

69

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

1591-1599

1 reference

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1866-2

10.1007/S00280-012-1866-2

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1010839751

0 references

1 reference